title: MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats.
abstract: The systemic administration of the N-methyl-D-aspartate (NMDA) receptor antagonist, MK801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine) , has previously been found to reverse the motor response alterations that develop during long-term levodopa treatment of parkinsonian rats. To determine whether co-administration of MK801 with levodopa might prevent the initial appearance of these response changes, rats, rendered parkinsonian by a 6-hydroxydopamine lesion of the medial forebrain bundle, received either levodopa alone or levodopa with the NMDA receptor antagonist. After four weeks of treatment with levodopa alone, the duration of the turning response declined by 37% (P < 0.05) and the number of ineffectual levodopa injections had more than doubled (P < 0.05). MK801 co-treatment completely blocked the shortening in response duration and prevented the frequency of ineffectual levodopa injection from exceeding baseline levels in animals receiving levodopa alone. The total magnitude of the turning response to levodopa was not affected. These results suggest that NMDA receptor blockade may act prophylactically to prevent the appearance of motor response alterations in levodopa-treated parkinsonian rodents that resemble those occurring in levodopa-treated patients with Parkinson's disease.
authors.affiliation: Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.
authors.forename: C
authors.initials: C
authors.lastname: Marin
authors.forename: S
authors.initials: S
authors.lastname: Papa
authors.forename: T M
authors.initials: TM
authors.lastname: Engber
authors.forename: M
authors.initials: M
authors.lastname: Bonastre
authors.forename: E
authors.initials: E
authors.lastname: Tolosa
authors.forename: T N
authors.initials: TN
authors.lastname: Chase
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D001545:Benserazide / Q000494:pharmacology; D016291:Dizocilpine Maleate / Q000494:pharmacology*; D007980:Levodopa / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000494:pharmacology; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D016627:Oxidopamine; D010300:Parkinson Disease / Q000503:physiopathology*; D016548:Prosencephalon; D051381:Rats; D017207:Rats, Sprague-Dawley; D012399:Rotation
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa; D016291:Dizocilpine Maleate; D001545:Benserazide; D016627:Oxidopamine; C035420:levodopa methyl ester